BMS Korea, Boryung co-market Baraclude in Korea

BMS Korea, a Korean branch of Bristol-Myers Squibb, and Boryung Pharm announced last Friday that the two companies have signed an agreement to co-promote Baraclude (entecavir) in Korea from next January.

Baraclude is an oral antiviral drug used in the treatment of hepatitis B infection. Baraclude is a guanine analogue that inhibits all three steps in the viral replication process, and it is ...